Lausanne-based Xsensio has raised new capital to push its Lab-on-Skin platform toward clinical use, aiming to make biochemical data as continuously available as today’s vital signs. The Swiss deep-tech startup says its wearable sits on the skin and samples biomarkers from interstitial fluid, generating near real-time readings rather than periodic lab snapshots. The Series A comes as hospitals and health systems look for earlier warning signals of deterioration in high-risk patients.
Financing round and syndicate
Xsensio said it closed an oversubscribed $7 million Series A financing led by WI Harper, with participation from Privilège Ventures, the European Innovation Council and additional private investors. The company has framed the round as a step toward accelerating product engineering and clinical validation, with an eye on broader deployment beyond acute care settings. In LinkedIn posts around the announcement, backers and the company described the raise as support for bringing multiplex biochemical monitoring into routine care and scaling manufacturing capability.
How the biosensing platform works
At the heart of the system is a miniaturized sensing chip that originated from research at EPFL’s NanoLab and was developed to integrate multiple sensors on a semiconductor substrate. Xsensio combines nanotechnology, biochemistry and microfluidics so the same core architecture can be configured to detect metabolites, ions, proteins and hormones from interstitial fluid. The company argues that multiplex measurement on a single device could enable richer physiological profiles than single-analyte wearables.
Clinical focus and validation plans
The initial commercial focus is early detection of organ dysfunction, with Xsensio targeting intensive care, oncology and post-surgical recovery populations where rapid changes can be missed between standard tests. The firm says continuous tracking of inflammation-related markers and other biochemical signals could help clinicians spot subtle decline sooner and adjust treatment earlier. Xsensio reports it is working with reference hospitals and industrial partners to validate the technology and tailor panels to specific clinical workflows.
Scaling from lab performance to manufacturable devices
Alongside the fundraise, Xsensio announced a long-term collaboration with Texas Instruments focused on CMOS integration, further miniaturization and manufacturability at scale. Executives from the company have said the goal is to translate laboratory-grade sensing performance into reliable, cost-effective hardware that can be produced consistently. The partnership is intended to strengthen Xsensio’s path from prototype devices to industrialized products suitable for hospital procurement and, eventually, wider healthcare use.
Track record and sector context
Xsensio has previously signaled its hospital ambitions through a 2023 partnership with Mayo Clinic, described as a collaboration to explore wearable products for earlier detection of acute health events. That earlier announcement highlighted a 5x5mm Lab-on-Skin chip designed to continuously collect and analyze biochemical data from interstitial fluid, supporting both in-hospital and remote monitoring scenarios. In broader market context, European media has pointed to sustained investor interest in continuous and wearable biosensing startups as the field tries to move beyond activity tracking and glucose-only biochemical wearables.
If Xsensio’s approach proves clinically robust, it could shift monitoring from intermittent testing toward continuous biochemical insight that is available at the bedside or at home. The company plans to use the Series A proceeds to advance engineering and clinical studies while building manufacturing readiness through its semiconductor partnership. For now, the latest raise signals investor confidence that multiplex biosensing can become a practical layer in modern patient monitoring.